About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Effect of Indacaterol on Inspiratory Capacity (IC)

NCT01012765·21 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novartis Pharmaceuticals

Age

40–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Co-operative outpatients with a diagnosis of COPD (moderate as classified by the GOLD Guidelines, 2008) and including:
* Smoking history of at least 10 pack years
* Post-bronchodilator FEV1 \<80% and ≥50% of the predicted normal value (Visit 2).
* Post-bronchodilator FEV1/forced vital capacity (FVC) \<70% (Visit 2).

You may not be if

Patients who received any corticosteroid (including inhaled) for 3 months prior to screening

The record

StatusCompleted

PhasePhase 3

Taking part173

StartedNov 2009

UpdatedFeb 17, 2016

Conditions

Chronic Obstructive Pulmonary Disease

Where21

Novartis Investigative Site
Aschaffenburg, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Dresden, Germany

Clareo Health | Effect of Indacaterol on Inspiratory Capacity (IC)